Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 1, 2011, Pages 54-61

  Zhang, Wenjun ^a   McElhinny, Abigail ^a   Nielsen, Alma ^a   Wang, Maria ^a   Miller, Melanie ^a   Singh, Shalini ^a   Rueger, Ruediger ^b   Rubin, Brian P ^c   Wang, Zhen ^c   Tubbs, Raymond R ^c   Nagle, Raymond B ^a   Roche, Pat ^d   Wu, Ping ^a   Pestic Dragovich, Lidija ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE DIAGNOSTICS GMBH   (Germany)

^c CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIGENIN; DNA; PROTEIN MDM2;

ANIMAL CELL; ARTICLE; BRIGHT FIELD MICROSCOPY; CELL LINE; CHONDROSARCOMA; CHROMOSOME 12; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; EMBRYONAL RHABDOMYOSARCOMA; GENE AMPLIFICATION; HISTIOCYTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDIZATION; IN SITU HYBRIDIZATION; LIPOMA; LIPOSARCOMA; METAPHASE; MICROSCOPE; MORPHOLOGY; MOUSE; NONHUMAN; ONCOGENE; OSTEOSARCOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; SOFT TISSUE; SYNOVIAL SARCOMA; TONSIL; TUMOR CELL;

ANEUPLOIDY; ANIMALS; CHROMOSOMES, HUMAN, PAIR 12; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION; IN SITU HYBRIDIZATION, FLUORESCENCE; MICE; OLIGONUCLEOTIDE PROBES; PROTO-ONCOGENE PROTEINS C-MDM2; SARCOMA;

EID: 78650839507     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181ee8e14     Document Type: Article

References (22)

1. Zhang R, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Design. 2000;6:393-416.
2. Momand J, Jung D, Wilczynski S, et al. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26:3453-3459.
3. Rayburn E, Zhang RW, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Current Cancer Drug Targets. 2005;5:27-41.
4. Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well differentiated liposarcoma. J Molecular Diagnos 2008;10:608-609.
5. Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Modern Pathol. 2009;22:66-70.
6. Shangary S, Ding K, Qiu S, et al. Targeting the MDM2-p53 interaction for cancer therapy. Clini Cancer Res. 2008;17:5318-5324.
7. Elkahloun AG, Bittner GM, Hoskins K, et al. Molecular cytogenetic characterization and physical mapping of 12q13 to 12q15 amplification in human cancers. Genes Chromosomes & Cancer. 1996;17:205-214.
8. Fischer U, Keller A, Leidinger P, et al. A different view on DNA amplifications indicates frequent, highly complex, and stable amplicons on 12q13 to 12q21 in glioma. Molecular Cancer Res. 2008;6: 576-584.
9. Marynen P, Kucherlapati R. Report of the third international workshop on human chromosome 12 mapping 1995. Cytogenetics Cell Genetics. 1996;73:1-19.
10. Reifenberger G, Ichimura K, Reifenberger J, et al. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 1996;56:5141-5145.
11. Italiano A, Bianchini L, Keslair F, et al. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. Int J Cancer. 2008;122:2233-2241.
12. Sirvent N, Coindre JM, Maire G, et al. Detection of MDM2-CDK4 amplification by fluorescence in situ hybridization in 200 paraffinembedded tumor samples: Utility in diagnosing adipocytic lesions and comparison with immunohistochemistry and real-time PCR. Am J Surg Pathol. 2007;31:1476-1489.
13. Gaiser T, Waha A, Moessler F, et al. Comparison of automated silver enhanced in situ hybridization and fluorescence in situ hybridization for evaluation of epidermal growth factor receptor status in human glioblastomas. Modern Pathol. 2009;22:1263-1271.
14. Beck RC, Tubbs RR, Hussein M, et al. Automated colorimetric in situ hybridization (CISH) detection of immunoglobulin (Ig) light chain mRNA expression in plasma cell (PC) dyscrasias and non-Hodgkin lymphoma. Diagnos Molecular Pathol. 2003;12:14-20.
15. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH). Diagnostic Pathol. 2008;3:41.
16. Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the Cdk4 Gene with MDM2 and Gli in Human Sarcomas. Cancer Res. 1993;53:5535-5541.
17. Looijenga LHJ, Smit VTHBM, Wessels JW, et al. Localization and Polymorphism of a Chromosome 12-Specific Alpha-Satellite DNASequence. Cytogenetics and Cell Genetics. 1990;53:216-218.
18. Pilotti S, Della Torre G, Mezzelani A, et al. The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer. 2000;82:1271-1275.
19. Hostein I, Pelmus M, Aurias A, et al. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol. 2004;202:95-102.
20. Tos APD, Doglioni C, Piccinin S, et al. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol. 2000;190:531-536.
21. Binh MBN, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes-A comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29:1340-1347.
22. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303: 844-848.